New Drug Exposes Hidden Subtypes of Psychosis

Summary: A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the first new schizophrenia drug mechanism approved in 50 years. Patients with strong negative symptoms responded best…

Continue Reading


News Source: neurosciencenews.com

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *